封面
市場調查報告書
商品編碼
1085749

社區肺炎細菌性肺炎(CABP)治療藥的全球市場:各類藥物,各劑型,各給藥途徑,各流通管道,各地區 - 規模,佔有率,展望,機會分析,(2022年~2028年)

Community-acquired Bacterial Pneumonia Treatment Drugs Market, by Drug Class, by Dose Form, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球社區肺炎細菌性肺炎(CABP)治療藥市場上,主要企業間的無機策略提升各公司的市場佔有率。可是,對藥物的抗生素的抗性,妨礙市場成長。

本報告提供全球社區肺炎細菌性肺炎(CABP)治療藥市場相關調查分析,推動市場要素與阻礙因素,市場機會,COVID-19影響,各藥物類別、劑型、給藥途徑、流通管道、地區的市場分析,競爭情形等。

目錄

第1章 調查目的、前提條件

第2章 市場範圍

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各類藥物
    • 市場明細:各劑型
    • 市場明細:各給藥途徑
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態、法規、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 償付情境
  • 流行病學
  • PEST分析
  • 法規情境
  • 新產品的銷售
  • 聯盟與協定
  • 市場趨勢

第4章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:COVID-19流行的影響

  • COVID-19市場情境
  • COVID-19對社區肺炎細菌性肺炎(CABP)治療藥產品市場的影響

第5章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:各類藥物(2017年~2028年)

  • 簡介
  • Pleuromutilin抗生素
  • 頭孢菌素
  • Glycylcycline
  • Oxazolidinone
  • Ketolide
  • 其他

第6章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:各劑型(2017年~2028年)

  • 簡介
  • 液劑
  • 錠劑

第7章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:各給藥途徑(2017年~2028年)

  • 簡介
  • 口服
  • 靜脈注射

第8章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:各流通管道(2017年~2028年)

  • 簡介
  • 院內藥局
  • 零售藥局
  • 線上藥局

第9章 全球社區肺炎細菌性肺炎(CABP)治療藥市場:各地區(2017年~2028年)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第10章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Nabriva Therapeutics
    • Paratek Pharmaceuticals, Inc.
    • Melinta Therapeutics, Inc.
    • Allergan plc
    • Bayer AG
    • Lupin Pharmaceuticals, Inc.
    • Mylan NV
    • Sanofi SA
    • Pfizer Inc.
    • Dainippon Sumitomo Pharma
    • Takeda Pharmaceutical Company Limited
    • Basilea Pharmaceutica International AG
    • Analyst Views

第11章 Section

簡介目錄
Product Code: CMI4269

Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.

.

Market Dynamics

Inorganic strategies amongst key players are strengthening the companies' market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.

However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2021 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Key features of the study:

  • This report provides in-depth analysis of the global community-acquired bacterial pneumonia (CABP) treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Detailed Segmentation:

  • Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class:
    • Pleuromutilin Antibiotic
    • Cephalosporin
    • Glycylcycline
    • Oxazolidinone
    • Ketolide
    • Others
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form:
    • Solution
    • Tablet
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration:
    • Oral
    • Intravenous
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region:
    • North America
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Pleuromutilin Antibiotic
      • Cephalosporin
      • Glycylcycline
      • Oxazolidinone
      • Ketolide
      • Others
      • By Dose Form:
      • Solution
      • Tablet
      • By Route of Administration
      • Oral
      • Parental
      • Topical
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Nabriva Therapeutics*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Paratek Pharmaceuticals, Inc.
    • Melinta Therapeutics, Inc.
    • Allergan plc
    • Bayer AG
    • Lupin Pharmaceuticals, Inc.
    • Mylan N.V.
    • Sanofi S.A.
    • Pfizer Inc.
    • Dainippon Sumitomo Pharma
    • Takeda Pharmaceutical Company Limited
    • Basilea Pharmaceutica International AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Dose Form
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Products

5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Pleuromutilin Antibiotic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Glycylcycline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Oxazolidinone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Ketolide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Solution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Tablet
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Nabriva Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Paratek Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Melinta Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Lupin Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dainippon Sumitomo Pharma
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Basilea Pharmaceutica International AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact